Retatrutide vs tirzepatide: should I switch / wait?
If tirzepatide is working, stay. If plateaued and curious, wait for retatrutide's Phase 3 readouts (TRIUMPH-1, 2026-2027) before chasing research-chem. Phase 2 showed 24.2% weight loss at 12 mg / 48 weeks, real but not a categorical leap over tirzepatide's ~22% best case. The novel glucagon agonism raises long-term questions Phase 3 is designed to answer.
Last reviewed · Panya.health editorial
What retatrutide actually adds over tirzepatide
Tirzepatide is a GLP-1 + GIP dual agonist. Retatrutide adds glucagon receptor agonism on top of the same GLP-1 + GIP backbone, making it a triple agonist. Glucagon raises hepatic glucose output (which is why it's a hyperglycemia signal in untreated diabetes) but also raises energy expenditure and lipid oxidation. In obese non-diabetic adults, the energy-expenditure effect dominates and produces additional weight loss beyond what GLP-1 + GIP alone deliver. Phase 2 (Jastreboff 2023 NEJM) showed 17.5% / 22.8% / 24.2% mean weight loss at 4 / 8 / 12 mg respectively over 48 weeks. SURMOUNT-1 tirzepatide best-case at 15 mg / 72 weeks was 22.5%. Head-to-head trials don't yet exist but the apples-to-apples comparison is roughly: retatrutide at 12 mg / 48 weeks ≈ tirzepatide at 15 mg / 72 weeks, with retatrutide perhaps slightly ahead. Not a categorical leap, more a marginal extension.
Why waiting for Phase 3 actually matters for retatrutide specifically
The wait-vs-research-chem trade-off is meaningfully different from tirzepatide's was in 2022-2023. With tirzepatide, the molecule had years of GLP-1 / GIP human exposure data through SURPASS (T2D) trials before SURMOUNT-1 (obesity) launched; the safety signal at the time of research-chem availability was already mature. Retatrutide's glucagon component is genuinely novel. The long-term cardiovascular, hepatic, and glycemic-control effects are what Phase 3 (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3) is designed to measure. Phase 2 (48 weeks, n=338) is too small and too short to surface the safety signals that matter for a multi-year compound. Research-chem retatrutide today is a bet against unknown safety endpoints; research-chem tirzepatide in 2023 was a bet against quality/sourcing only. Different risk profile.
When switching from working tirzepatide makes sense
Mostly: it doesn't, yet. If tirzepatide is producing your target weight loss without intolerable side effects, the marginal upside of retatrutide (a few percentage points) is not worth the safety unknowns or the supply-chain risk. The one case where switching might make sense: documented plateau at maximum tolerated tirzepatide dose (15 mg) for 6+ months with no further weight movement, plus poor T2D context (since glucagon agonism could worsen poorly-controlled T2D, this is actually a contraindication, not an indication, for diabetic users). The cleaner path for plateaued tirzepatide users is enrolling in a retatrutide Phase 3 site (Lilly's TRIUMPH program), which gets you the molecule under medical supervision with real safety monitoring, no sourcing risk, no cost.
Where Panya stands
Retatrutide is documented at panya.health/peptide/retatrutide with full mechanism, Phase 2 data, and the Phase 3 wait-vs-act framing. Tirzepatide is documented at panya.health/compound/tirzepatide and panya.health/peptide/tirzepatide with regional pricing pages for 17 markets. Panya routes to licensed clinicians for tirzepatide today; we do NOT route to research-chem retatrutide because the safety case for waiting is materially stronger than for established compounds. The honest read on the choice between these two is: for almost everyone who's not already in a Phase 3 trial, the answer is to keep tirzepatide working until Phase 3 retatrutide readouts land, then re-evaluate.
Read about these peptides
Retatrutide is Eli Lilly's triple agonist of the GLP-1, GIP, and glucagon receptors, currently in Phase 3 weight-loss trials. Phase 2 showed 24% body weight loss at 12 mg / 48 weeks, the strongest published GLP-1-class e...
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's disease. Phase 2 trials in obesity showed weight loss roughly twice that of historical anti-...
Related posts
Tirzepatide monthly cost across 10 markets: US brand, US compounded, UK private, Scandinavia, Germany, Thailand clinic, Thailand direct, Japan, Singapore, Australia. The real numbers, updated April 20...
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.